Tvardi Therapeutics, Inc. 8-K

What Happened

• Tvardi Therapeutics, Inc. filed an 8-K on March 6, 2026 announcing its 2026 Annual Meeting of Stockholders will be held on June 9, 2026. The filing describes how and when stockholder proposals and director nominations must be submitted to be included in the company’s proxy materials or otherwise considered.

Key Details

• Annual meeting date: June 9, 2026.
• Deadline to be considered for inclusion in the proxy statement under SEC Rule 14a-8: proposals received on or before March 16, 2026 will be treated as timely.
• Bylaws advance-notice deadline for nominations or other matters (later of 90th day prior or 10th day after announcement): March 16, 2026 for the 2026 meeting.
• Universal proxy (SEC Rule 14a-19) notice deadline for stockholders intending to solicit proxies for nominees other than the company’s nominees: April 10, 2026.

Why It Matters

• If you want to submit a proposal to appear in Tvardi’s proxy statement or nominate a director, you must meet these specific deadlines and content requirements; proposals should be sent to the company’s principal executive offices.
• Missing the advance-notice deadlines can allow the company’s proxies to vote discretionarily on late proposals at the meeting, which may limit a stockholder’s ability to place items or nominees on the ballot.
• This filing does not report financial results, officer changes, or other corporate actions — it only sets the meeting date and procedural deadlines.